GURUFOCUS.COM » STOCK LIST » USA » NAS » Vertex Pharmaceuticals Inc (NAS:VRTX) » Definitions » Price-to-Owner-Earnings
Switch to:

Vertex Pharmaceuticals Price-to-Owner-Earnings

: 22.93 (As of Today)
View and export this data going back to 1991. Start your Free Trial

As of today (2022-08-11), Vertex Pharmaceuticals's share price is $296.74. Vertex Pharmaceuticals's Owner Earnings per Share (TTM) ended in Jun. 2022 was $12.94. It's Price-to-Owner-Earnings for today is 22.93.


The historical rank and industry rank for Vertex Pharmaceuticals's Price-to-Owner-Earnings or its related term are showing as below:

VRTX' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 18.11   Med: 46.44   Max: 581.51
Current: 22.85

During the past 13 years, the highest Price-to-Owner-Earnings of Vertex Pharmaceuticals was 581.51. The lowest was 18.11. And the median was 46.44.


VRTX's Price-to-Owner-Earnings is ranked better than
64.33% of 171 companies
in the Biotechnology industry
Industry Median: 31.96 vs VRTX: 22.85

As of today (2022-08-11), Vertex Pharmaceuticals's share price is $296.74. Vertex Pharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2022 was $12.37. Therefore, Vertex Pharmaceuticals's PE Ratio for today is 23.99.

As of today (2022-08-11), Vertex Pharmaceuticals's share price is $296.74. Vertex Pharmaceuticals's EPS without NRI for the trailing twelve months (TTM) ended in was $12.37. Therefore, Vertex Pharmaceuticals's PE Ratio without NRI for today is 23.99.

During the past 13 years, Vertex Pharmaceuticals's highest PE Ratio without NRI was 560.57. The lowest was 19.37. And the median was 29.67.


Vertex Pharmaceuticals Price-to-Owner-Earnings Historical Data

The historical data trend for Vertex Pharmaceuticals's Price-to-Owner-Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vertex Pharmaceuticals Annual Data
Trend Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21
Price-to-Owner-Earnings
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 286.54 53.47 44.48 21.21 27.44

Vertex Pharmaceuticals Quarterly Data
Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22
Price-to-Owner-Earnings Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 31.12 27.63 27.44 32.91 21.78

Competitive Comparison

For the Biotechnology subindustry, Vertex Pharmaceuticals's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

   

Vertex Pharmaceuticals Price-to-Owner-Earnings Distribution

For the Biotechnology industry and Healthcare sector, Vertex Pharmaceuticals's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where Vertex Pharmaceuticals's Price-to-Owner-Earnings falls into.



Vertex Pharmaceuticals Price-to-Owner-Earnings Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

Vertex Pharmaceuticals's Price-to-Owner-Earnings for today is calculated as

Price-to-Owner-Earnings=Share Price/Owner Earnings per Share (TTM)
=296.74/12.94
=22.93

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Vertex Pharmaceuticals  (NAS:VRTX) Price-to-Owner-Earnings Explanation

For how to get Owner Earnings per Share (TTM), please click.


Vertex Pharmaceuticals Price-to-Owner-Earnings Related Terms

Thank you for viewing the detailed overview of Vertex Pharmaceuticals's Price-to-Owner-Earnings provided by GuruFocus.com. Please click on the following links to see related term pages.


Vertex Pharmaceuticals Business Description

Vertex Pharmaceuticals logo
Address
50 Northern Avenue, Boston, MA, USA, 02210
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Executives
Upadhyay Suketu director 345 E. MAIN STREET WARSAW IN 46580
Garber Alan M director 3355 MILTON COURT MOUNTAIN VIEW CA 94040
Kearney Terrence C director IN CARE OF HOSPIRA, INC. 275 NORTH FIELD DRIVE LAKE FOREST IL 60045
Carney Lloyd director C/O MICROMUSE INC 139 TOWNSEND ST SAN FRANCISCO CA 94107
Mckenzie Diana director METLIFE 200 PARK AVENUE NEW YORK NY 10166
Bhatia Sangeeta N. director C/O VERTEX PHARMACEUTICALS, INC. 50 NORTHERN AVENUE BOSTON MA 02210
Lee Yuchun director 170 TRACER LA. WALTHAM MA 02451
Ambrose Kristen officer: SVP & Chief Accounting Officer C/O VERTEX PHARMACEUTICALS INCORPORATED 50 NORTHERN AVENUE BOSTON MA 02210
Mcglynn Margaret G director C/O MERCK & CO INC ONE MERCK DRIVE PO BOX 100 WHITEHOUSE STATION NJ 08889-0100
Liu Joy officer: SVP, General Counsel C/O VERTEX PHARMACEUTICALS INCORPORATED 50 NORTHERN AVENUE BOSTON MA 02210
Tatsis Ourania officer: EVP, Chief Reg. & Quality Off. C/O VERTEX PHARMACEUTICALS, INC. 50 NORTHERN AVENUE BOSTON MA 02210
Bozic Carmen officer: EVP and CMO C/O VERTEX PHARMACEUTICALS, INC. 50 NORTHERN AVENUE BOSTON MA 02210
Wagner Charles F Jr officer: EVP & Chief Financial Officer C/O MILLIPORE CORP BILLERICA MA 01820
Arbuckle Stuart A officer: EVP, COO VERTEX PHARMACEUTICALS INCORPORATED 130 WAVERLY ST. CAMBRIDGE MA 02139
Kewalramani Reshma director, officer: CEO & President C/O VERTEX PHARMACEUTICALS, INC. 50 NORTHERN AVENUE BOSTON MA 02210

Vertex Pharmaceuticals Headlines

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)